Overall survival at 5 years of follow-up in a phase III trial… Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg_kg with 3 mg_kg in patients with advanced melanoma RETOUR MarcGuevreguian2021-03-22T20:35:56+01:00
